Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Pre-clinical models demonstrate the ability of sclerostin inhibition with a neutralizing antibody to heal lytic lesions and restore bone health in myeloma by reversing Wnt suppression and altering osteoblasts and osteo-CAR cells.”
Title: Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Authors: Hayley M. Sabol, Aric Anloague, Japneet Kaur, Cecile Bustamante-Gomez, Sharmin Khan, Bethany C. Paxton, Mattie R. Nester, Jillian Hackney, Marta Diaz-delCastillo, Daniel Mann, Jeffrey B. Stambough, C. Lowry Barnes, Elena Ambrogini, Alison Frontier, Frank H. Ebetino, Syed Naqvi, Frits van Rhee, Christopher P. Wardell, Matthew T. Drake, Intawat Nookaew, Carolina Schinke, Maurizio Zangari, Jesus Delgado-Calle
You can read the Full Article on Experimental Hematology and Oncology.
You can find more posts featuring Robert Orlowski on OncoDaily.
